NANOPARTICULATE SORAFENIB FORMULATIONS

The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorfaneib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the com...

CARTY Sarah，JENKINS Scott，LIVERSIDGE Gary - WO

Gel stabilized nanoparticulate active agent compositions

Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in ...

SL Mcgurk，DA Czekai - EP

Bioactive particulates having a cationic surfactant adsorbed on their surfaces to provide superior adhesion to a biological substrate, e.g., an insect, tee...

Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surfa...

H Bosch，E Cooper，S Mcgurk - US

NANOPARTICULATE MEGESTROL FORMULATIONS

The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Douglas HOVEY，J Pruitt，T Ryde - US

NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

CJ Bloom，MD Crew，WK Miller，... - US

Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/faste...

The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particle...

T Ryde，EE Gustow，SB Ruddy，... - WO

In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions

Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

ER Cooper，JA Bullock，JR Chippari，... - US

NANOPARTICULATE SORAFENIB FORMULATIONS

The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the com...

S Carty，S Jenkins，G Liversidge - EP

TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

GUIDO Debora，HUANG Haiyong Hugh

Method for preparing submicron particles of antineoplastic agents

The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogen...

M Chaubal，J Werling，B Rabinow - US